Design, synthesis, and biological evaluation of benzofuran- and 2,3-dihydrobenzofuran-2-carboxylic acid N-(substituted)phenylamide derivatives as anticancer agents and inhibitors of NF-κB. 2015

Minho Choi, and Hyeju Jo, and Hyun-Jung Park, and Arepalli Sateesh Kumar, and Joonkwang Lee, and Jieun Yun, and Youngsoo Kim, and Sang-Bae Han, and Jae-Kyung Jung, and Jungsook Cho, and Kiho Lee, and Jae-Hwan Kwak, and Heesoon Lee
Department of Pharmacy, Chungbuk National University, Chungbuk 362-763, Republic of Korea.

With the aim of developing novel scaffolds as anticancer agents and inhibitors of NF-κB activity, 60 novel benzofuran- and 2,3-dihydrobenzofuran-2-carboxylic acid N-(substituted)phenylamide derivatives (1a-s, 2a-k, 3a-s, and 4a-k) were designed and synthesized from the reference lead compound KL-1156, which is an inhibitor of NF-κB translocation to the nucleus in LPS-stimulated RAW 264.7 macrophage cells. The novel benzofuran- and 2,3-dihydrobenzofuran-2-carboxamide derivatives exhibited potent cytotoxic activities (measured by the sulforhodamine B assay) at low micromolar concentrations against six human cancer cell lines: ACHN (renal), HCT15 (colon), MM231 (breast), NUGC-3 (gastric), NCI-H23 (lung), and PC-3 (prostate). In addition, these compounds also inhibited LPS-induced NF-κB transcriptional activity. The +M effect and hydrophobic groups on the N-phenyl ring potentiated the anticancer activity and NF-κB inhibitory activity, respectively. However, according to the results of structure-activity relationship studies, only benzofuran-2-carboxylic acid N-(4'-hydroxy)phenylamide (3m) was the lead scaffold with both an outstanding anticancer activity and NF-κB inhibitory activity. This novel lead scaffold may be helpful for investigation of new anticancer agents that act through inactivation of NF-κB.

UI MeSH Term Description Entries
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002264 Carboxylic Acids Organic compounds containing the carboxy group (-COOH). This group of compounds includes amino acids and fatty acids. Carboxylic acids can be saturated, unsaturated, or aromatic. Carboxylic Acid,Acid, Carboxylic,Acids, Carboxylic
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000577 Amides Organic compounds containing the -CO-NH2 radical. Amides are derived from acids by replacement of -OH by -NH2 or from ammonia by the replacement of H by an acyl group. (From Grant & Hackh's Chemical Dictionary, 5th ed) Amide
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy

Related Publications

Minho Choi, and Hyeju Jo, and Hyun-Jung Park, and Arepalli Sateesh Kumar, and Joonkwang Lee, and Jieun Yun, and Youngsoo Kim, and Sang-Bae Han, and Jae-Kyung Jung, and Jungsook Cho, and Kiho Lee, and Jae-Hwan Kwak, and Heesoon Lee
February 2012, Biochimie,
Minho Choi, and Hyeju Jo, and Hyun-Jung Park, and Arepalli Sateesh Kumar, and Joonkwang Lee, and Jieun Yun, and Youngsoo Kim, and Sang-Bae Han, and Jae-Kyung Jung, and Jungsook Cho, and Kiho Lee, and Jae-Hwan Kwak, and Heesoon Lee
August 2010, Bioorganic & medicinal chemistry letters,
Minho Choi, and Hyeju Jo, and Hyun-Jung Park, and Arepalli Sateesh Kumar, and Joonkwang Lee, and Jieun Yun, and Youngsoo Kim, and Sang-Bae Han, and Jae-Kyung Jung, and Jungsook Cho, and Kiho Lee, and Jae-Hwan Kwak, and Heesoon Lee
September 2023, Bioorganic & medicinal chemistry letters,
Minho Choi, and Hyeju Jo, and Hyun-Jung Park, and Arepalli Sateesh Kumar, and Joonkwang Lee, and Jieun Yun, and Youngsoo Kim, and Sang-Bae Han, and Jae-Kyung Jung, and Jungsook Cho, and Kiho Lee, and Jae-Hwan Kwak, and Heesoon Lee
September 2021, Bioorganic & medicinal chemistry,
Minho Choi, and Hyeju Jo, and Hyun-Jung Park, and Arepalli Sateesh Kumar, and Joonkwang Lee, and Jieun Yun, and Youngsoo Kim, and Sang-Bae Han, and Jae-Kyung Jung, and Jungsook Cho, and Kiho Lee, and Jae-Hwan Kwak, and Heesoon Lee
July 2017, European journal of medicinal chemistry,
Minho Choi, and Hyeju Jo, and Hyun-Jung Park, and Arepalli Sateesh Kumar, and Joonkwang Lee, and Jieun Yun, and Youngsoo Kim, and Sang-Bae Han, and Jae-Kyung Jung, and Jungsook Cho, and Kiho Lee, and Jae-Hwan Kwak, and Heesoon Lee
December 2015, Bioorganic chemistry,
Minho Choi, and Hyeju Jo, and Hyun-Jung Park, and Arepalli Sateesh Kumar, and Joonkwang Lee, and Jieun Yun, and Youngsoo Kim, and Sang-Bae Han, and Jae-Kyung Jung, and Jungsook Cho, and Kiho Lee, and Jae-Hwan Kwak, and Heesoon Lee
January 2020, Bioorganic chemistry,
Minho Choi, and Hyeju Jo, and Hyun-Jung Park, and Arepalli Sateesh Kumar, and Joonkwang Lee, and Jieun Yun, and Youngsoo Kim, and Sang-Bae Han, and Jae-Kyung Jung, and Jungsook Cho, and Kiho Lee, and Jae-Hwan Kwak, and Heesoon Lee
August 2016, Bioorganic & medicinal chemistry letters,
Minho Choi, and Hyeju Jo, and Hyun-Jung Park, and Arepalli Sateesh Kumar, and Joonkwang Lee, and Jieun Yun, and Youngsoo Kim, and Sang-Bae Han, and Jae-Kyung Jung, and Jungsook Cho, and Kiho Lee, and Jae-Hwan Kwak, and Heesoon Lee
February 2015, Organic & biomolecular chemistry,
Minho Choi, and Hyeju Jo, and Hyun-Jung Park, and Arepalli Sateesh Kumar, and Joonkwang Lee, and Jieun Yun, and Youngsoo Kim, and Sang-Bae Han, and Jae-Kyung Jung, and Jungsook Cho, and Kiho Lee, and Jae-Hwan Kwak, and Heesoon Lee
February 2020, European journal of medicinal chemistry,
Copied contents to your clipboard!